BTG Licenses Alzheimer's Compounds To Senexis And Co-Invests £1 Million With The Wellcome Trust
London and Cambridge, UK, 2 February 2006 - BTG plc (LSE: BGC), the medical innovations company, and Senexis Limited, a private drug development company, announce today that BTG has exclusively licensed its novel inhibitors of amyloid-induced toxicity and neuroinflammation to Senexis. These compounds may be useful in the treatment of Alzheimer's Disease and other amyloid-based diseases. BTG will receive milestones payments as the compounds progress though development and future royalties on eventual sales. The first milestones will be triggered by candidate selection and approval to commence clinical studies.
"We are delighted to license these novel compounds to Senexis," commented Louise Makin, BTG's Chief Executive Officer. "We believe Senexis' platform and expertise in protecting cells and tissues from amyloid-induced toxicity makes it the ideal partner to take these innovative compounds forwards.”
Mark Treherne, Senexis' Chief Executive, commented: “We are pleased that Senexis has been able to in-license these compounds to add to our existing portfolio of novel compounds. We look forward to being able to accelerate their development towards the clinic.”
BTG and the technology transfer division of the Wellcome Trust also announce that they have each invested £500,000 into Senexis to enable the company to progress preclinical development of its small molecule Alzheimer's programmes. BTG and the Wellcome Trust provided initial funding of £1.4 million to Senexis in November 2002.
The number of people with Alzheimer's disease is expected to double over the next two decades. Currently, five million people in the US alone are affected by the disease.
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741
+44 (0)20 7831 3113
Mark Treherne, Chief Executive
+44 (0)1223 496160
Senexis is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia, type II diabetes and Parkinson's disease. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of these different diseases. Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is funded by BTG plc and the Wellcome Trust. Further information on Senexis can be found at www.senexis.com.
BTG acquires rights to early stage pharmaceuticals and other medical technologies from a global network of corporations, universities and research institutions. We apply resources, including finance, intellectual property and project management skills to fund and manage outsourced preclinical and clinical development programs. We then commercialise the technologies by licensing to pharmaceutical or device companies, or by creating companies to exploit them. Our pipeline comprises around 50 assets at varying stages of development, contributing to an increasing range of products marketed by our licensees. BTG operates from London, Philadelphia and Osaka. For further information, visit www.btgplc.com.
About the Wellcome Trust
The Wellcome Trust is an independent research-funding charity established in 1936 under the will of tropical medicine pioneer Sir Henry Wellcome. The Trust's mission is to promote research with the aim of improving human and animal health and it currently spends more than £400m p.a. The Technology Transfer Division manages the charity's intellectual property portfolio and related matters and provides translation funding for early-stage healthcare technology development. Over 70 research and license agreements have been transacted and the division has an interest in around 20 life science Small, Medium Enterprises located in the UK or US.Back to press releases